514 related articles for article (PubMed ID: 34991659)
21. Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model.
Zhang Q; Le K; Xu M; Zhou J; Xiao Y; Yang W; Jiang Y; Xi Z; Huang T
Int Immunopharmacol; 2019 Nov; 76():105864. PubMed ID: 31480004
[TBL] [Abstract][Full Text] [Related]
22. Triple-negative breast cancer influences a mixed M1/M2 macrophage phenotype associated with tumor aggressiveness.
Pe KCS; Saetung R; Yodsurang V; Chaotham C; Suppipat K; Chanvorachote P; Tawinwung S
PLoS One; 2022; 17(8):e0273044. PubMed ID: 35960749
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
[TBL] [Abstract][Full Text] [Related]
24. CD44v5 domain regulates crosstalk between TNBC cells and tumor-associated macrophages by enhancing the IL-4R/STAT3 axis.
Dai Y; Ji Z; Liang H; Jiang M; Wang L; Bao X; Liu J; Liu M; Yang C
Cancer Sci; 2024 May; ():. PubMed ID: 38700108
[TBL] [Abstract][Full Text] [Related]
25. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
[TBL] [Abstract][Full Text] [Related]
26. Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer.
Long L; Xu J; Qi X; Pen Y; Wang C; Jiang W; Peng X; Hu Z; Yi W; Xie L; Lei X; Wang Z; Zhuo L
Eur J Med Chem; 2024 Jul; 273():116500. PubMed ID: 38776807
[TBL] [Abstract][Full Text] [Related]
27. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
28. Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells.
Du J; Wang L; Huang X; Zhang N; Long Z; Yang Y; Zhong F; Zheng B; Lan W; Lin W; Ma W
Phytomedicine; 2021 May; 85():153551. PubMed ID: 33827043
[TBL] [Abstract][Full Text] [Related]
29. Nano-inducer of ferroptosis for targeted chemotherapy of human triple negative breast carcinoma.
Shetake NG; Das SK; Kumar A; Pandey BN
Biomater Adv; 2024 Jul; 161():213868. PubMed ID: 38677038
[TBL] [Abstract][Full Text] [Related]
30. G6PD activation in TNBC cells induces macrophage recruitment and M2 polarization to promote tumor progression.
Li Y; Han X; Lin Z; Wang C; Fu Z; Sun Q; Li C
Cell Mol Life Sci; 2023 May; 80(6):165. PubMed ID: 37237244
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of cancerous progression by LISCH7 via direct stimulation of TGFB1 transcription in triple-negative breast cancer.
Tang X; Zhou Y; Liu Y; Zhang W; Liu C; Yan C
J Cell Biochem; 2020 Nov; 121(11):4642-4653. PubMed ID: 32048750
[TBL] [Abstract][Full Text] [Related]
32. PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer.
Qi L; Sun B; Yang B; Lu S
Breast Cancer Res Treat; 2022 Jun; 193(2):305-318. PubMed ID: 35325342
[TBL] [Abstract][Full Text] [Related]
33. Protein-Bound Polysaccharides from
Jędrzejewski T; Pawlikowska M; Sobocińska J; Wrotek S
Cell Physiol Biochem; 2020 Jun; 54(4):615-628. PubMed ID: 32559360
[TBL] [Abstract][Full Text] [Related]
34. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
35. Enhanced Therapeutic Effect of Optimized Melittin-dKLA, a Peptide Agent Targeting M2-like Tumor-Associated Macrophages in Triple-Negative Breast Cancer.
Kim S; Choi I; Han IH; Bae H
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555393
[TBL] [Abstract][Full Text] [Related]
36. Gallium maltolate shows synergism with cisplatin and activates nucleolar stress and ferroptosis in human breast carcinoma cells.
Chen CH; Huang YM; Grillet L; Hsieh YC; Yang YW; Lo KY
Cell Oncol (Dordr); 2023 Aug; 46(4):1127-1142. PubMed ID: 37067747
[TBL] [Abstract][Full Text] [Related]
37. PGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis.
Zhao Y; Ruan X; Cheng J; Xu X; Gu M; Mueck AO
Climacteric; 2023 Apr; 26(2):135-142. PubMed ID: 36724820
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
Wang S; Yao Y; Yao M; Fu P; Wang W
Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
[TBL] [Abstract][Full Text] [Related]
39. The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
Sami E; Paul BT; Koziol JA; ElShamy WM
Cancer Res; 2020 Mar; 80(5):1102-1117. PubMed ID: 31911557
[TBL] [Abstract][Full Text] [Related]
40. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
